pharma news today obesity drugs glp-1 october 2025 2024 was a record year for trials and is already poised to take over Obesity GLP-1 Market Size to

This case highlights the need for gradual insulin tapering and close monitoring while transitioning from insulin therapy to GIP/GLP-1 receptor agonists.

Find the best new GLP-1 drug for you.

The role of GLP-1 RAs was also investigated using the Inverse Probability Treatment Weighting (IPTW) and in the subgroup analyses

CONTRIBUTED BY REAL CHEMISTRY | BY RITA GLAZE-ROWE ALABAMA A new study on behalf of Real Chemistry has identified which state Medicaid programs cover GLP-1s.The growing popularity of GLP-1 receptor agonists including Ozempic and Wegovy from Novo Nordisk, and Mounjaro and Zepbound from Eli Lilly has added fuel to an already fiery []

Thats why we created National Adverse Drug Event Awareness Day

A new GLP-1 oral medication from AstraZeneca, known as elecoglipron, lowered blood sugar levels and led to 10.5% weight loss in a phase 2b clinical trial.